HC Wainwright Comments on G1 Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Stock analysts at HC Wainwright upped their Q2 2024 EPS estimates for shares of G1 Therapeutics in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their prior forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for G1 Therapeutics’ Q3 2024 earnings at ($0.17) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.61) EPS and FY2025 earnings at ($0.20) EPS.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, May 1st. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same period last year, the firm posted ($0.53) EPS.

Several other research analysts have also recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $5.00 target price (up from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of G1 Therapeutics in a report on Wednesday, May 1st.

G1 Therapeutics Stock Performance

Shares of GTHX opened at $4.27 on Monday. The firm has a market capitalization of $223.24 million, a P/E ratio of -6.89 and a beta of 1.71. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.94 and a quick ratio of 2.55. G1 Therapeutics has a one year low of $1.08 and a one year high of $5.00. The business has a fifty day moving average of $3.98 and a 200 day moving average of $3.13.

Hedge Funds Weigh In On G1 Therapeutics

Several large investors have recently added to or reduced their stakes in GTHX. abrdn plc purchased a new position in shares of G1 Therapeutics in the fourth quarter worth $1,293,000. Raymond James & Associates lifted its holdings in shares of G1 Therapeutics by 16.9% in the third quarter. Raymond James & Associates now owns 925,776 shares of the company’s stock worth $1,333,000 after buying an additional 133,662 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of G1 Therapeutics in the third quarter worth $189,000. FinTrust Capital Advisors LLC lifted its holdings in shares of G1 Therapeutics by 154,946.2% in the fourth quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock worth $307,000 after buying an additional 100,715 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after purchasing an additional 82,879 shares during the last quarter. Hedge funds and other institutional investors own 24.21% of the company’s stock.

Insider Buying and Selling at G1 Therapeutics

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the transaction, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 8.23% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.